Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
40 studies found for:    PRO-140 OR PRO-140[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Recruiting Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
Conditions: HIV;   Human Immunodeficiency Virus
Intervention: Drug: PRO 140 350mg weekly SQ injection.
2 Completed Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
Condition: HIV Infections
Intervention: Drug: PRO 140
3 Completed
Has Results
PRO 140 by IV Administration in Adults With HIV-1 Infection
Condition: HIV Infections
Interventions: Drug: PRO 140;   Drug: Placebo
4 Recruiting PRO 140 for Human Immunodeficiency Virus Infection
Condition: HIV
Intervention: Biological: PRO 140
5 Completed
Has Results
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
Conditions: HIV -1 Infection;   HIV Infections
Interventions: Drug: PRO 140 (humanized monoclonal antibody to CCR5);   Drug: Placebo Comparator
6 Not yet recruiting A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Condition: HIV
Interventions: Drug: PRO 140;   Drug: Placebo
7 Completed A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma
Condition: Allergic Asthma
Intervention: Drug: HAE1 (PRO98498)
8 Completed Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.
Condition: Hypertension
Intervention: Drug: valsartan/atenolol
9 Active, not recruiting Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: ustekinumab;   Drug: placebo
10 Active, not recruiting Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: ustekinumab;   Drug: placebo
11 Active, not recruiting Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: placebo
12 Terminated Study of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection
Condition: Severe Sepsis
Intervention: Other: Procalcitonin level
13 Unknown  Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury
Condition: Pediatric Traumatic Brain Injury
Interventions: Drug: Probenecid and N-acetyl cysteine;   Drug: Placebo
14 Terminated
Has Results
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel;   Drug: Carboplatin plus Paclitaxel
15 Recruiting Predicting Weight Gain and Weight Loss Associated With Overeating or Fasting
Conditions: Obesity;   Diet Therapy;   Weight Loss;   Weight Gain;   Nutrition Therapy
Interventions: Behavioral: Weight Loss;   Behavioral: Overfeeding;   Behavioral: Overfeeding Low Pro
16 Active, not recruiting
Has Results
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Conditions: Hypertension, Pulmonary;   Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
17 Completed
Has Results
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Rosiglitazone;   Drug: Sulfonylurea;   Drug: Metformin
18 Completed Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: INSULIN GLARGINE (HOE901);   Drug: Insulin aspart;   Drug: Insulin Glulisine
19 Recruiting Evaluation of Quality of Care - Multi-disciplinary Risk Assessment and Management Programme for Patients With Hypertension, HA (QoC RAMP-HT)
Condition: Hypertension
Intervention:
20 Recruiting Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Condition: Heart Failure
Interventions: Drug: Vericiguat (BAY1021189) (1.25 mg);   Drug: Vericiguat (BAY1021189) (5 mg);   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years